The Gene Logic biorepository consists of a high-quality, diverse collection of human tissue samples and extracted DNA specimens with linked clinical information. The 60,000 samples and specimens cover multiple disease areas, including many thousands of cancer tissue specimens.

 

"This transaction significantly strengthens Transgenomic's position in translational medicine services, providing a deep source of clinical samples allowing us to validate new drug-associated genetic targets," said Craig Tuttle, CEO of Transgenomic. "The biorepository provides not only strategic and operational benefits, but also long-term cost savings. Acquiring specimens on a case-by-case basis is expensive and time-consuming; such expenditure would quickly surpass the cost of acquiring this asset."